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INTRODUCTION 
Human tuberculosis (TB) is caused by infection with 
members of the Mycobacterium tuberculosis complex, 
which includes Mycobacterium tuberculosis itself, 
Mycobacterium africanum, Mycobacterium bovis, 
Mycobacterium caprae, Mycobacterium microti, 
Mycobacterium pinnipedii and Mycobacterium canettii1,2. 
Patients with active pulmonary TB are the main sources 
of infection and the majority of people infected with M. 
tuberculosis contain it as asymptomatic latent TB 
infection (LTBI). An estimated 2 billion people have 
LTBI and are at risk of re-activation of the disease1,3,4. 
TB continues to spread in every corner of the globe 
despite the introduction of the inexpensive and effective 
quadruple drug therapy regimen 40 years ago 5 
The seventeenth World Health Organization (WHO) 
report on the worldwide incidence of TB6 indicates that 
TB remains a global emergency. India, China, South 
Africa and the Russian Federation have almost 60% of 
the world‟s TB cases6` Multidrug-resistant TB 
(MDR-TB) is now widespread globally with an esti-
mated half a million cases reported in 2011, and 
extensively drug-resistant TB (XDR-TB) has been 
reported in 84 countries. 
TB treatment is challenging, requiring accurate and early 
diagnosis, drug-resistance screening and the 
administration of effective treatment regimens for at least 
6 months through directly observed therapy (DOT) and 
follow-up support. There is an urgent need for the devel-
opment and more efficient evaluation of new TB drugs 
and shorter treatment regimens.. Over the past 10 years, 
significant investment by scientists, funding bodies and 
high-profile advocacy by the WHO‟s STOP TB depart-
ment, and other organizations, has led to a renaissance of 
activity in the discovery and development of new TB 
drugs and TB treatment regimens. These efforts have 
culminated in historic advances in TB therapeutics, 
including the recent submissions to regulatory agencies 
for approval of two new drugs: delamanid (previously 
known as OPC67683) and bedaquiline (also known as 
TMC207 or R207910) 
CURRENT TUBERCULOSIS TREATMENT 
REGIMENS  
Drug-susceptible tuberculosis. Nearly 60 years follow-
ing the identification of the first antibiotic active against 
M. tuberculosis, the current recommended treatment of 
drug-susceptible TB is of at least 6 months duration and 
achieves cure rates of >95% when administered under 
DOT. Treatment requires a minimum of 6 months in two 
phases: 2 months of four drugs (isoniazid, rifampicin, 
pyrazinamide and ethambutol) in the intensive phase 
followed by 4 months of isoniazid plus rifampicin in the 
continuation stage (the so-called short-course chemo-
therapy). This regimen is currently implemented for 
pulmonary TB and most forms of extrapulmonary TB 
regardless of HIV status7,8. 
However, there are significant challenges associated with 
current therapy including the following: drug intolerance 
and toxicities, with the resultant need for treatment 
interruptions and changes to the regimen; 
pharmacokinetic drug–drug interactions, particularly 
with antiretroviral therapy (ART) drugs in patients 
co-infected with TB and HIV; and patient adherence 
given the lengthy treatment duration necessary to achieve 
non-relapsing cure. The absence of concerted drug 
development and new combinations for decades has 
paradoxically paved the way for introduction of fixed-
dose combinations of two (isoniazid and rifampicin), 
three (isoniazid, rifampicin and pyrazinamide) and four 
(isoniazid, rifampicin, pyrazinamide and ethambutol) 
drugs9. Given that most of the world‟s TB burden is 
caused by drug-susceptible strains of M. tuberculosis, the 
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above two, three and four fixed-dose combinations have 
been introduced in an attempt to decrease the emergence 
of resistance and to improve ease of administration. 
However, challenges with the existing standard treatment 
regimen remain and continue to impede progress in 
global TB control. 
Multidrug-resistant-TB.(Tuberculosis  caused by 
Mycobacterium tuberculosis bacilli that are resistant to at 
least isoniazid and rifampicin) The WHO estimates that 
only 10% of the annual 650,000 incident cases of 
MDR-TB worldwide receive high-quality, appropriate 
treatment and management. Ideally, treatment of 
MDR-TB requires „individualized‟ regimens based on in 
vitro drug-susceptibility testing (DST) results for each 
patient‟s isolate10. In areas where facilities for M. 
tuberculosis culture are available, culture-based systems 
for first-line DST do not provide results for several 
weeks, and for second-line DST the results are frequently 
not available for several months.Patient groups for which 
empirical treatment for MDR-TB is considered, and 
offered, include those in whom TB treatment is failing 
(that is, who remain culture-positive after 4 months of 
treatment), any persons with recurrent TB, persons in 
contact with drug-resistant cases of TB, and persons who 
were born in countries, or reside in settings, where drug-
resistant TB is highly prevalent.  
The newly introduced Xpert MTB/RIF Assay is a 
diagnostic test that can be used with minimal technical 
expertise, enabling rapid diagnosis of TB and simul-
taneous assessment of rifampicin resistance within 2 
hours11,12. The test is fully automated and utilizes molec-
ular beacon technology to detect DNA sequences ampli-
fied in a hemi-nested real-time PCR assay. MTB/RIF 
assay provides a high sensitivity initial screen for 
MDR-TB and the WHO recommends that patients with 
rifampicin-resistant TB should receive MDR-TB therapy 
pending additional DST 
The 2011 WHO MDR-TB treatment guidelines recom-
mend that the intensive phase of therapy is administered 
for at least 8 months for patients newly diagnosed with 
MDR-TB (that is, not previously treated for MDR-TB)10. 
Regimens should include at least four second-line drugs 
(BOX 1) that will have nearly certain effectiveness and 
be given on a daily basis under DOT throughout the 
treatment duration. Total duration of therapy should be 
for at least 20 months when there is no history of 
previous MDR-TB treatment, and 28 months if there was 
previous MDR treatment. Pyrazinamide (Group 1; BOX 
1) and an injectable drug (Group 2; BOX 1) are given 
only during the intensive phase. Durations for each phase 
should be modified according to the patient‟s response to 
therapy. Group 3 (BOX 1) contains the fluoroquinolones, 
of which moxifloxacin and levofloxacin are most active. 
Other approved second-linedrugs for MDR-TB treatment 
included in Group 4 and Group 5 (BOX 1) have either 
weak or unclear bacteriostatic activity, many of which 
also have very high rates of side effects and intolerance. 
Linezolid (an oxazolidinone) and clofazimine (a 
riminophenazine) are two drugs in Group 5 that are 
undergoing additional investigation to better define their 
safety, tolerability and efficacy as potential repurposed 
drugs for MDR-TB . 
 
 Box 1  
CLASSIFICATION OF DRUGS USED TO TREAT DRUG-SUSCEPTIBLE AND DRUG-          RESISTANT 
TUBERCULOSIS
13  
First-line anti-TB drugs  
Group 1. Oral: isoniazid (H/Inh), rifampicin/rifampin (R/Rif), pyrazinamide (Z/Pza), ethambutol (E/Emb), rifapentine 
(P/Rpt) or rifabutin (Rfb).  
Second-line anti-TB drugs  
Group 2. Injectable aminoglycosides: streptomycin (S/Stm), kanamycin (Km), amikacin (Amk). Injectable 
polypeptides: capreomycin (Cm), viomycin (Vim).  
Group 3. Oral and injectable fluoroquinolones: ciprofloxacin (Cfx), levofloxacin (Lfx), moxifloxacin (Mfx), ofloxacin 
(Ofx), gatifloxacin (Gfx).  
Group 4. Oral: para-aminosalicylic acid (Pas), cycloserine (Dcs), terizidone (Trd), ethionamide (Eto), prothionamide 
(Pto), thioacetazone (Thz) 
Third-line anti-TB drugs  
Group 5. Clofazimine (Cfz), linezolid (Lzd), amoxicillin plus clavulanate (Amx/Clv), imipenem plus cilastatin 
(Ipm/Cln), clarithromycin (Clr).  
 
Extensively drug-resistant TB  
(XDR-TB). Tuberculosis (TB) caused by Mycobacterium 
tuberculosis bacilli that are resistant to rifampicin, 
isoniazid, plus any fluoroquinolone and at least one of 
the three injectable second-line drugs: amikacin, 
kanamycin and capreomycin  . XDR-TB takes 
substantially longer to treat than MDR-TB and requires 
the use of third-line anti-TB drugs, which are expensive 
and often have more side effects than first-line or 
second-line drugs. XDR-TB is associated with high mor-
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tality rates and in HIV-infected persons these may reach 
100% if treatment commences too late14,15. 
Totally drug-resistant tuberculosis. Some recent reports 
use the term totally drug-resistant TB (TDR-TB) to 
describe TB caused by M. tuberculosis strains that are 
resistant to all available first-line and second-line TB 
drugs16Labelling patients as having TDR-TB is likely to 
generate additional and unnecessary stigma, and as such 
should be avoided, particularly given the serious 
concerns raised by the WHO. Moreover, since new drugs 
are being developed and evaluated to combat drug-
resistant strains of M. tuberculosis, and many drugs are 
being repurposed, the categorization will soon become 
obsolete. 
NEW ANTI-TUBERCULOSIS DRUG 
DEVELOPMENT 
After five decades of near inactivity in TB drug devel-
opment, the past 5 years have seen the emergence of a 
promising TB drug pipeline. Combining these new drugs 
with existing TB drugs offers hope for regimens that are 
better tolerated, shorter in duration and with fewer drug–
drug interactions when compared with existing regimens.  
Repurposed compounds  
Many of the candidates currently in clinical trials are 
drugs that were developed to treat other infectious dis-
eases and have since been repurposed. 
Fluoroquinolones. Fluoroquinolones target DNA gyrase 
and DNA topoisomerase in many bacteria and are fre-
quently used for the treatment of MDR-TB as 
components Interest in their use as possible first-line 
drugs was renewed when it was shown that fluo-
roquinolones had the potential to reduce the duration of 
therapy in murine models of TB17Gatifloxacin and 
moxifloxacin  are currently in Phase III clinical trials to 
establish whether drug-susceptible TB can be effectively 
treated in 4 months by substituting gatifloxacin for 
ethambutol, or moxifloxacin for ethambutol or 
isoniazid18 
Rifamycins. Rifampicin, which has been the backbone of 
TB chemotherapy for 40 years, targets the beta subunit 
of RNA polymerase, thereby preventing transcription. 
Rifapentine , another rifamycin, acts in the same way but 
has a much longer half-life than rifampicin, so achieves 
better exposure and thus has the potential to shorten 
treatment duration19. Several Phase II clinical trials are in 
progress, in which rifampicin is replaced by high-dose 
rifapentine, to assess its potential to shorten the treatment 
duration of drug-susceptible TB 
Clofazimine. A meta-analysis of studies that used the 
leprosy drug clofazimine repurposed for TB treatment 
showed that it could have a major part to play in the 
treatment of MDR-TB20 Clofazimine administration via 
the aerosol route using microparticles was effective in 
the treatment of a mouse model of TB21. This route of 
administration could potentially reduce the 
gastrointestinal and dermatological (skin discolouration) 
side effects of Clofazimine 
Oxazolidinones. Oxazolidinones are a new class of drugs 
that inhibit protein synthesis by binding to the 23S rRNA 
in the 50S ribosomal subunit of bacteria. Linezolid, a 
first-generation oxazolidinone  shows tuberculostatic 
activity in vitro and modest activity in murine models of 
TB22,23. Early off-label trials of linezolid in combination 
regimens suggested that the drug was effective against 
MDR-TB23 and definitive proof for this was recently 
obtained in a prospective, randomized clinical trial in 
patients with XDR-TB24 Apart from peripheral neurop-
athy and myelosuppression, several other serious side 
effects of linezolid occur, such as thrombocytopaenia 
and optic neuritis25. 
Sutezolid (also known as PNU-100480), a linezolid 
analogue that has stronger bactericidal activity in the 
murine model than linezolid, is currently in Phase II 
clinical trials26,27 
Meropenem plus clavulanate combination. M. 
tuberculosis is naturally resistant to β-lactam antibiotics, 
such as meropenem, as it produces an efficient β-
lactamase, BlaC, which hydrolyses them. Recently, it 
was elegantly demonstrated that inhibition of BlaC by 
clavulanate could lead to M. tuberculosis becoming 
susceptible to meropenem28 Meropenem acts by 
inhibiting dd-carboxypeptidase activity, thereby 
perturbing peptidoglycan biosynthesis29. Meropenem and 
clavulanate are both approved drugs and this 
combination has been used with some success, in 
conjunction with other drugs, to treat patients with 
MDR-TB and XDR-TB30,31 
NEW CHEMICAL ENTITIES  
Bedaquiline. The newly approved drug bedaquiline, a 
diarylquinoline inhibits the c subunit of ATP synthase, 
thereby decreasing intracellular ATP levels32 
Bedaquiline was discovered using phenotypic screening 
An attractive feature of bedaquiline is its equipotent 
activity against both replicating and dormant M. tuber-
culosis bacilli33, and an explanation for this was provided 
by Rao et al.34, who showed that de novo ATP synthesis 
is essential for the viability of nonreplicating 
mycobacteria. Bedaquiline kills both drug-susceptible 
and drug-resistant M. tuberculosis strains, displaying 
minimal inhibitory concentrations equal to or lower than 
those of isoniazid and rifampicin The clinical activity of 
bedaquiline validates ATP synthase as a highly 
vulnerable target of M. tuberculosis. Another remarkable 
feature of bedaquiline is its unusually long half-life, a 
desirable feature for inclusion of this drug in an intermit-
tent regimen35. However, bedaquiline also accumulates 
in tissues, therefore care must be taken to avoid carry-
over effects when measuring its activity36. Bedaquiline 
has a black-box warning due to its potential to induce 
arrhythmia13.  
Nitroimidazoles. Nitroimidazole compounds, such as the 
classic metronidazole, were first investigated as TB 
drugs because of their known activity against anaerobic 
microorganisms, and anaerobiosis is thought to lead to 
LTB37. Metronidazole kills M. tuberculosis in vitro under 
hypoxic but not aerobic conditions and displays widely 
contrasting effects in different animal models, ranging 
from good efficacy in the rabbit, with its caseous granu-
lomas, to no efficacy in mice or guinea pigs. Two newer 
nitroimidazoles, PA-824  and OPC67683 (now known as 
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delamanid) are in clinical development, and, like 
metronidazole, both are prodrugs. 
Delamanid is a nitro-dihydro-imidazooxazole that was 
first shown to be active against M. tuberculosis in vitro 
and then in mice38. Its mechanism of action is probably 
through inhibiting mycolic acid biosynthesis and it also 
kills intracellular tuberculosis bacilli. Like PA-824, dela-
manid requires nitroreduction by Ddn for activation; 
mutants lacking this enzyme are resistant to delamanid 
and unable to produce the des-nitro-imidazooxazole 
form38-42. It seems probable that delamanid, which is 
more potent than PA-824, also kills by producing NO or 
an as yet unidentified radical, and that this acts randomly 
within M. tuberculosis.  Delamanid received its first 
global approval in the European Union (EU), for use in 
combination with optimised background therapy., for the 
treatment of MDR-TB.43In a recent study, delamanid 
improved treatment outcome and reduced mortality 
among MDR-TB and XDR-TB patients when used with 
an optimized background regimen44.  
Benzothiazinones. Benzothiazinones  are the most potent 
inhibitors of M. tuberculosis yet described and display 
low nanomolar bactericidal activity against mycobacteria 
growing in vitro and in ex vivo models45Benzothiazinone 
derivatives are therefore suicide substrates and BTZ043 
is now at the good laboratory practice toxicology stage of 
preclinical development. 
PROGRESS IN NEWER TREATMENT 
REGIMENS FOR MDR-TB. 
 Recent studies have brought additional treatment options 
for MDR-TB. An observational “Bangladesh” 
standardized regimen study46 with a duration of 9–12 
months evaluated the efficacy of gatifloxacin, 
ethambutol, pyrazinamide and clofazimine given 
throughout the study, supplemented by kanamycin, 
prothionamide and isoniazid during an intensive phase of 
4 months. The study concluded that outcomes were 
comparable with those observed with the usual 20-month 
course of MDR-TB treatment and that major adverse 
drug reactions were infrequent. 
CONCLUSIONS AND PERSPECTIVES  
TB is now found in every corner of the globe and is 
threatening gains made in TB control in Europe 47,48. 
This is despite the introduction of cheap and effective 
treatment with quadruple drug therapy 40 years ago. 
There is a great need for shorter, less toxic treatment 
regimens, new drugs and better and shorter ways of 
evaluating new TB drugs and drug regimens. The history 
and evolution of TB drug discovery, development and 
evaluation has been fascinating. Over the past 10 years a 
major investment by scientists, funders and the WHO has 
led to a renaissance of activity into new TB drug 
development and evaluation. There is an urgent need for 
increased coordination and enhanced collaboration 
among drug developers, funding agencies and clinical 
trial networks. Efforts by the Critical Path to TB Drug 
Regimens are underway to bring stakeholders together to 
develop shorter, more effective TB treatment regimens 
for the therapy of both drug-susceptible and drug-
resistant TB, and can be progressed more quickly using 
newer clinical trial designs guided by more specific 
biomarkers.
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